Press releases
2022
8 November, 2022
Interim report January-September 2022
19 August, 2022
Interim report Q2 2022
19 May, 2022
Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue
26 April, 2022
Interim report January-March 2022
20 April, 2022
Egetis Therapeutics’ 2021 annual report published
13 April, 2022
Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue
21 March, 2022
Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million